Immunovant Other Non Cash Items vs Change To Operating Activities Analysis

IMVT Stock

USD 23.78 0.90 3.65%

Immunovant financial indicator trend analysis is infinitely more than just investigating Immunovant recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunovant is a good investment. Please check the relationship between Immunovant Other Non Cash Items and its Change To Operating Activities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.

Other Non Cash Items vs Change To Operating Activities

Other Non Cash Items vs Change To Operating Activities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunovant Other Non Cash Items account and Change To Operating Activities. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Immunovant's Other Non Cash Items and Change To Operating Activities is -0.65. Overlapping area represents the amount of variation of Other Non Cash Items that can explain the historical movement of Change To Operating Activities in the same time period over historical financial statements of Immunovant, assuming nothing else is changed. The correlation between historical values of Immunovant's Other Non Cash Items and Change To Operating Activities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Non Cash Items of Immunovant are associated (or correlated) with its Change To Operating Activities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Operating Activities has no effect on the direction of Other Non Cash Items i.e., Immunovant's Other Non Cash Items and Change To Operating Activities go up and down completely randomly.

Correlation Coefficient

-0.65

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Other Non Cash Items

Change To Operating Activities

Most indicators from Immunovant's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunovant current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.At this time, Immunovant's Tax Provision is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 1.4 B in 2025, whereas Selling General Administrative is likely to drop slightly above 41.1 M in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	208.3M	282.7M	438.2M	460.1M
Research Development	160.3M	225.4M	360.9M	379.0M

Total Operating Expenses Research Development

Immunovant fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Accounts Payable	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital
Total Assets		0.9	0.91	1.0	0.95	0.75	0.98	0.78	0.9	0.91	1.0	0.21	0.65	-0.94	-0.96	-0.87	1.0	0.7	0.94	1.0	0.31	0.97	0.0	0.98	-0.87	1.0
Other Current Liab	0.9		0.99	0.89	0.82	0.77	0.92	0.95	0.98	0.98	0.9	0.03	0.5	-0.87	-0.95	-0.97	0.91	0.8	0.92	0.91	0.19	0.9	0.0	0.9	-0.85	0.91
Total Current Liabilities	0.91	0.99		0.9	0.84	0.86	0.92	0.94	0.98	1.0	0.91	0.06	0.55	-0.87	-0.97	-0.97	0.92	0.85	0.93	0.92	0.31	0.9	0.02	0.9	-0.85	0.92
Total Stockholder Equity	1.0	0.89	0.9		0.95	0.75	0.98	0.78	0.9	0.91	1.0	0.21	0.66	-0.94	-0.96	-0.87	1.0	0.7	0.94	1.0	0.31	0.97	-0.01	0.97	-0.87	1.0
Net Tangible Assets	0.95	0.82	0.84	0.95		0.7	0.96	0.65	0.79	0.85	0.95	0.43	0.83	-0.98	-0.91	-0.73	0.95	0.62	0.95	0.95	0.38	0.98	0.03	0.97	-0.91	0.95
Accounts Payable	0.75	0.77	0.86	0.75	0.7		0.71	0.75	0.83	0.87	0.75	0.02	0.51	-0.68	-0.83	-0.81	0.77	0.84	0.76	0.77	0.61	0.69	-0.05	0.69	-0.65	0.77
Common Stock Shares Outstanding	0.98	0.92	0.92	0.98	0.96	0.71		0.79	0.89	0.92	0.98	0.24	0.66	-0.96	-0.95	-0.86	0.98	0.67	0.95	0.98	0.27	0.99	0.03	1.0	-0.91	0.98
Other Current Assets	0.78	0.95	0.94	0.78	0.65	0.75	0.79		0.96	0.93	0.78	-0.13	0.36	-0.72	-0.88	-0.98	0.8	0.89	0.82	0.8	0.01	0.76	-0.03	0.76	-0.71	0.8
Other Stockholder Equity	0.9	0.98	0.98	0.9	0.79	0.83	0.89	0.96		0.98	0.9	-0.02	0.5	-0.84	-0.97	-0.99	0.91	0.87	0.91	0.91	0.21	0.86	-0.04	0.86	-0.81	0.91
Total Liab	0.91	0.98	1.0	0.91	0.85	0.87	0.92	0.93	0.98		0.91	0.08	0.56	-0.88	-0.97	-0.97	0.93	0.85	0.93	0.93	0.31	0.9	0.02	0.9	-0.86	0.92
Total Current Assets	1.0	0.9	0.91	1.0	0.95	0.75	0.98	0.78	0.9	0.91		0.21	0.65	-0.94	-0.96	-0.87	1.0	0.7	0.94	1.0	0.31	0.97	0.0	0.98	-0.87	1.0
Short Long Term Debt Total	0.21	0.03	0.06	0.21	0.43	0.02	0.24	-0.13	-0.02	0.08	0.21		0.64	-0.35	-0.15	0.11	0.21	0.02	0.24	0.21	0.16	0.34	0.66	0.25	-0.54	0.2
Property Plant And Equipment Net	0.65	0.5	0.55	0.66	0.83	0.51	0.66	0.36	0.5	0.56	0.65	0.64		-0.83	-0.66	-0.41	0.67	0.52	0.79	0.67	0.31	0.71	-0.01	0.68	-0.72	0.66
Current Deferred Revenue	-0.94	-0.87	-0.87	-0.94	-0.98	-0.68	-0.96	-0.72	-0.84	-0.88	-0.94	-0.35	-0.83		0.93	0.78	-0.94	-0.65	-0.98	-0.94	-0.31	-0.97	0.04	-0.96	0.9	-0.94
Net Debt	-0.96	-0.95	-0.97	-0.96	-0.91	-0.83	-0.95	-0.88	-0.97	-0.97	-0.96	-0.15	-0.66	0.93		0.94	-0.98	-0.81	-0.97	-0.98	-0.32	-0.94	0.02	-0.93	0.88	-0.98
Retained Earnings	-0.87	-0.97	-0.97	-0.87	-0.73	-0.81	-0.86	-0.98	-0.99	-0.97	-0.87	0.11	-0.41	0.78	0.94		-0.88	-0.86	-0.87	-0.88	-0.15	-0.82	0.06	-0.83	0.76	-0.88
Cash	1.0	0.91	0.92	1.0	0.95	0.77	0.98	0.8	0.91	0.93	1.0	0.21	0.67	-0.94	-0.98	-0.88		0.72	0.95	1.0	0.32	0.97	-0.01	0.97	-0.88	1.0
Non Current Assets Total	0.7	0.8	0.85	0.7	0.62	0.84	0.67	0.89	0.87	0.85	0.7	0.02	0.52	-0.65	-0.81	-0.86	0.72		0.77	0.72	0.1	0.65	-0.02	0.64	-0.65	0.72
Non Currrent Assets Other	0.94	0.92	0.93	0.94	0.95	0.76	0.95	0.82	0.91	0.93	0.94	0.24	0.79	-0.98	-0.97	-0.87	0.95	0.77		0.95	0.28	0.95	-0.09	0.94	-0.88	0.95
Cash And Short Term Investments	1.0	0.91	0.92	1.0	0.95	0.77	0.98	0.8	0.91	0.93	1.0	0.21	0.67	-0.94	-0.98	-0.88	1.0	0.72	0.95		0.32	0.97	-0.01	0.97	-0.88	1.0
Net Receivables	0.31	0.19	0.31	0.31	0.38	0.61	0.27	0.01	0.21	0.31	0.31	0.16	0.31	-0.31	-0.32	-0.15	0.32	0.1	0.28	0.32		0.28	-0.02	0.29	-0.26	0.31
Common Stock Total Equity	0.97	0.9	0.9	0.97	0.98	0.69	0.99	0.76	0.86	0.9	0.97	0.34	0.71	-0.97	-0.94	-0.82	0.97	0.65	0.95	0.97	0.28		0.09	0.99	-0.93	0.97
Non Current Liabilities Total	0.0	0.0	0.02	-0.01	0.03	-0.05	0.03	-0.03	-0.04	0.02	0.0	0.66	-0.01	0.04	0.02	0.06	-0.01	-0.02	-0.09	-0.01	-0.02	0.09		-0.01	-0.38	-0.01
Capital Surpluse	0.98	0.9	0.9	0.97	0.97	0.69	1.0	0.76	0.86	0.9	0.98	0.25	0.68	-0.96	-0.93	-0.83	0.97	0.64	0.94	0.97	0.29	0.99	-0.01		-0.89	0.97
Deferred Long Term Liab	-0.87	-0.85	-0.85	-0.87	-0.91	-0.65	-0.91	-0.71	-0.81	-0.86	-0.87	-0.54	-0.72	0.9	0.88	0.76	-0.88	-0.65	-0.88	-0.88	-0.26	-0.93	-0.38	-0.89		-0.88
Net Invested Capital	1.0	0.91	0.92	1.0	0.95	0.77	0.98	0.8	0.91	0.92	1.0	0.2	0.66	-0.94	-0.98	-0.88	1.0	0.72	0.95	1.0	0.31	0.97	-0.01	0.97	-0.88

Click cells to compare fundamentals

Immunovant Account Relationship Matchups

Immunovant fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	412.5M	515.6M	405.8M	666.4M	776.2M	396.9M
Other Current Liab	14.0M	24.7M	40.8M	41.3M	51.0M	53.6M
Total Current Liabilities	18.8M	44.5M	43.3M	48.6M	68.8M	72.2M
Total Stockholder Equity	391.5M	469.8M	362.5M	617.8M	707.4M	363.2M
Net Tangible Assets	94.1M	391.5M	469.8M	362.5M	416.9M	242.7M
Accounts Payable	2.4M	18.6M	1.4M	7.2M	17.7M	18.5M
Common Stock Shares Outstanding	87.8M	109.7M	123.1M	138.1M	151.6M	93.2M
Liabilities And Stockholders Equity	412.5M	515.6M	405.8M	666.4M	776.2M	396.9M
Other Current Assets	7.7M	6.3M	26.9M	24.9M	51.2M	53.7M
Other Stockholder Equity	590.4M	824.8M	928.0M	1.4B	1.9B	2.0B
Total Liab	21.0M	45.7M	43.3M	48.6M	68.8M	72.2M
Total Current Assets	409.0M	512.9M	404.3M	665.8M	767.7M	394.5M
Accumulated Other Comprehensive Income	(298K)	404K	852K	1.9M	1.5M	1.5M
Short Long Term Debt Total	3.4M	2.4M	1.2M	138K	98K	93.1K
Property Plant And Equipment Net	3.5M	2.6M	1.5M	595K	942K	1.4M
Net Debt	(396.7M)	(491.5M)	(375.3M)	(635.2M)	(713.9M)	(678.2M)
Retained Earnings	(198.7M)	(355.4M)	(566.3M)	(825.7M)	(1.2B)	(1.2B)
Cash	400.1M	493.8M	376.5M	635.4M	714.0M	427.5M
Non Current Assets Total	3.5M	2.6M	1.5M	595K	8.6M	9.0M
Cash And Short Term Investments	400.1M	493.8M	376.5M	635.4M	714.0M	427.5M
Net Receivables	1.1M	12.9M	885K	5.5M	2.5M	4.5M
Common Stock Total Equity	5K	10K	12K	13K	15.0K	8.9K
Non Current Liabilities Total	2.2M	1.2M	47K	347K	1.1M	1.0M
Capital Surpluse	185.3M	590.4M	824.8M	928.0M	1.1B	556.3M
Net Invested Capital	391.5M	469.8M	362.5M	617.8M	707.4M	415.4M
Capital Stock	10K	12K	13K	14K	16K	11.0K
Net Working Capital	390.2M	468.4M	361.0M	617.2M	698.9M	413.2M
Short Term Debt	2.4M	1.1M	1.2M	138K	98K	93.1K
Common Stock	10K	12K	13K	14K	16K	11.0K
Property Plant Equipment	65K	201K	330K	333K	383.0K	216.3K
Capital Lease Obligations	3.4M	2.4M	1.2M	138K	98K	93.1K
Property Plant And Equipment Gross	3.5M	2.6M	1.5M	595K	942K	1.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC